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Hemodialysis vs. peritoneal dialysis: Results of a 3-year prospec-
tive controlled study. A prospective comparison of peritoneal
dialysis to hemodialysis was undertaken to identify advantages
and disadvantages of either treatment relative to the other. He-
matologic, biochemical, lipid, and neurobehavioral parameters
were followed. Careful controls were imposed to assure that the
treatment groups were comparable. Patients on peritoneal dial-
ysis proved to have more normal concentrations of BUN, hemo-
globin, potassium, bicarbonate, and high-density lipoproteins.
Hemodialysis patients had more normal concentrations of albu-
min, total protein, and calcium. Hypertriglyceridemia was only
minimally greater in peritoneal patients. Neurobehavioral results
documented multiple abnormalities in both. The profile of results
obtained provides preliminary criteria for selecting either form of
dialysis for a particular patient.
Hémodialyse ou dialyse péritonéale: Résultats d'une étude pro-
spective de 3 ans. Une comparaison prospective de l'hémodialyse
et de la dialyse péritonéale a été entreprise afin d'identifier les
avantages et les inconvénients de chacun des traitements par
rapport a l'autre. Les paramètres étudiés étaient hématolo-
giques biochimiques, neurologiques et comportementaux. Ii a
été vériflé que les deux groupes traités étaient comparables. Les
malades en dialyse péritonéale avaient des valeurs d'azote uré-
ique, d'hémoglobine, de potassium, de bicarbonate et de lipo-
protéines de haute densité plus proches de la normale. Les mal-
ades en hemodialyse avaient des valeurs d'albumine, de protides
totaux et de calcémie plus proches de Ia normale. L'hypertri-
glycéridémie était a peine plus importante chez les malades
en dialyse péritonéale. Les etudes neuro-comportementales ont
montré de nombreuses anomalies dans les deux groupes. Les
résultats obtenus apportent des critéres préliminaires de sé-
lection pour l'une des deux tactiques de traiternent.
Current interest in peritoneal dialysis (PD) stems
from its emergence as an apparently safe and suit-
able alternative to hemodialysis (HD) in treating
end-stage renal disease. Previous reports [1-7] sug-
gested that PD prolonged life and provided accept-
able rehabilitation but that it might cause worrisome
hypertriglyceridemia. More recently, it has been re-
ported [8] that patient withdrawal from PD, for vari-
ous reasons, is so great as to compromise the useful-
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ness of the method. No prospective studies of
matched populations were reported when our work
began, and the magnitude of the dialysis population
and effort was already so great that objective as-
sessment of advantages or disadvantages of PD and
HD seemed necessary. We therefore designed a
protocol to study patients treated with PD or HD,
and collected clinical, hematologic, biochemical,
lipid, and neurophysiologic data under controlled
conditions during the course of a 3.5-year-long pro-
spective study. Our purpose was to identify advan-
tages or disadvantages peculiar to either treatment,
so that selection of the more appropriate treatment
for patients would be facilitated.
Methods
Patients with end-stage renal disease requiring
dialysis were informed of the availability of both
HD and PD. After discussion of known benefits and
risks, each patient was permitted to choose the per-
sonally more attractive therapy, unless a known
medical contraindication existed. After treatment
selection, patients' records were examined to iden-
tify those in one group who were similar to those in
the other. When such a pair was identified, both pa-
tients were asked to participate in the study. After
we obtained informed consent, both patients were
entered simultaneously. Pairing criteria, population
characteristics, and average treatment schedules of
the 32 participants are shown in Table 1. Selection
of pairs was done by screening all patients for these
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Table 1. Average population pairing characteristicsa
Age, yr
Sex, male :female
Race, Black: White : other
Renal disease
Serum cholesterol, mg/dl
Mean arterial pressure, mm Hg
Smoking habits, packs/yr
Drinking habits
Previous transplant, yes : no
Length on dialysis, months
Residual renal function, b mi/mm
Residualurea clearance, mi/mm
Nephrotic syndrome, yes : no
Body surface area, m2
Dialysis treatment, hr/wk
Dialyzing surface area, m2
Numbers of patients are given in parentheses.
"(Urea clearance + creatinine clearance)/2
55 13 (so)9:7
2 : 14 : 0
Glomerulonephritis (1)
Interstitial neph. (1)
Polycystic kidneys (1)
Lupus (1)
Hypertension (2)
Diabetic nephropathy (7)
Obstruction (I)
Nephrosclerosis (1)
Congenital hypoplastic kidneys (1)
199 55
104 12
8.9 18.8
Light
I : 15
21 7
1.69 1.62
0.28 0.39
4 : 12
1.72 0.14
30 5
Hemodialysis
53 14
9:7
5: 11:0
Glomerulonephritis (4)
Pyelonephritis (2)
Polycystic kidneys (1)
Lupus (1)
Hypertension (1)
Diabetic nephropathy (7)
171 40
105 9
4.2 10.8
Light
2 : 14
29 18
1.35 1.47
0.27 0.38
4 : 12
1.70 0.17
11.2 2.7
2.1 0.5
criteria and attempting to pair those most alike with
one another. No patient was entered unless a com-
parable patient simultaneously entered the other
group. If any patient exited for any reason, the oth-
er member of that pair was simultaneously exited.
These procedures limited the number of patients en-
tered but assured comparability of the groups under
study at every point of time. The differences in
length of time on dialysis and residual renal function
were not significant.
Four hemodialysis patients used Gambro (13.7 or
17.0) dialyzers; two used Travenal Paraflow; the re-
mainder used Cordis-Dow dialyzers (C-DAK 4 or
C-DAK 5). The duration of dialysis ranged from 3 to
5 hours; the average time was 3.7 hours, 3 times
weekly, with a 2. l-m2 dialyzing surface. Peritoneal
dialysis patients received an average of 30 hours of
treatment weekly, and with one exception they
used Drake-Willock or Physiocontrol machines.
The single exception was dialyzed manually on a
regular basis.
It was understood and intended that the two
groups would not receive identical treatment, as the
membranes used and solute clearances necessarily
differed. We sought to determine whether such dif-
ferences in treatment produced advantages or dis-
advantages to the patients so treated. We did not
take over the management of the patients. Each was
treated by a managing nephrologist to obtain what
was considered an optimal degree of wellbeing.
Blood samples for hematologic and biochemical
tests were always obtained before dialysis. A con-
trol population for lipid studies was composed of
volunteers ranging in age from 27 to 66 years. None
of the volunteers had systemic disease, obesity,
personal or familial hyperlipidemia, or used medica-
tions known to affect lipid metabolism. All subjects
were fasted 12 to 16 hours prior to venous sampling.
Cholesterol was manually determined by the meth-
od of Abel! et al [9], triglycerides by the method of
Geigel, Ham, and Clema [10], lipoprotein quan-
tification by a standard protocol [1 1], postheparin
lipolytic activity by the method of Krauss, Levy,
and Frederickson [12], and free fatty acids [13] and
alpha1 acid glycoprotein [141 by standard methods.
The alpha1 determination used a commercially
available radial immunodiffusion kit (Behring Diag-
nostics).
Electroencephalographic observations were al-
ways made the day after a dialysis treatment. Stud-
ies included analysis of the quantified and comput-
erized EEG, visual evoked responses, and photic
driving responses of paired patients. Typical arti-
fact-free sections of EEG data lasting 48 seconds
(12-X-4-sec blocks) were selected and then were
frequency analyzed by computer. Activity within
certain frequency ranges was quantified to deter-
mine four different indices previously used by oth-
ers [15, 16]. Visual evoked responses were analyzed
according to Kooi and Bagchi [17]. Photic driving
Peritoneal
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responses were analyzed by a Fast Fourier Trans-
form program, and values were expressed as a ratio
based on the amplitude of response at the funda-
mental frequency.
One patient-pair was followed for 144 weeks; the
others were followed for periods ranging from 24 to
90 weeks. Comparisons were made on final, cu-
mulative group averages, so that all determinations
of hematocrit, for example, were averaged for each
group and then compared to all values for the other
group. Comparisons are of group to group, not of
individual to individual. This same technique for
data comparison was used for all results, and is the
basis for the data in Tables 2, 4, and 5. A computer
program was developed to aid in storage, retrieval,
and statistical analysis of the data acquired. Sixteen
patient-pairs participated in the hematologic and
biochemical studies, 7 pairs in lipid studies, and 6 in
electroencephalographic analyses.
Peritoneal Hemodialysis P
Hematocrit, %
Hemoglobin,gIdl
WBC, X lO3Imm
BUN, mg/dl
Creatinine,mg/dl
Na,mEq/liter
K,mEq/liter
C1, mEqiliter
HC03, mEqiliter
Ca,mg/d1
Phosphate, mg/d/
A1kP'tase,üm1
Bilirubin,mgldl
SGOT, pJml
LDH, u/mi
Totalprotein,g/di
Albumin, gidI
Uricacid,mg/dl
27.0 7.2
8.6 1.9
8.4 2.2
87.8 26.8
13.4 4.6
139 6.0
4.7 0.6
102.0 9.0
18.2 4.0
8.5 1.3
5.6 1.9
27.1 31.4
0.35 0.4
15.6 16.5
220 73
6.1 1.7
3.2 0.8
9.0 2.3
24.5 4.9
7.8 1.6
7.6 2.1
97 25.6
14.6 4.4
139 5.0
5.4 0.9
100.0 6.0
16.0 4.2
9.0 0.9
5.2 1.9
43.6 74.9
0.47 0.8
19.1 19.7
186.0 73
7.0 0.9
3.9 0.4
8.8 1.8
0.004
0.003
NS
0.008
NS
NS
<0.001
NS
0.006
<0.001
NS
NS
NS
NS
NS
<0.001
<0.001
NS
Walues are the means SD.
PD patients had more normal values for BUN,
Results serum bicarbonate and potassium concentrations. HD
patients had more normal values for total protein,
albumin, and calcium concentrations. Other values
noted in the table do not differ significantly.
Table 3 demonstrates no differences in morbid-
ity or mortality for the two groups after 5850 days
at risk for each group. Hospitalization for dialy-
sis access was virtually identical. Four patients
in the peritoneal population died, two in the HD
group died. This difference did not reach statistical
significance. All of the deaths were in diabetics, five
from arteriosclerotic heart disease, one from perito-
nitis.
Because of the difficulties in treating diabetics,
separate analysis was made of the seven pairs of
diabetic patients and compared with nondiabetic
patients (Table 4). In the diabetic patients, those on
PD had lower potassium and higher hematocrit and
bicarbonate levels. The total protein, albumin, and
calcium levels were, however, quite reduced com-
pared with HD patients, and the magnitude of the
difference was greater than it was in nondiabetics.
In the nondiabetic group, there was no significant
difference in total protein or calcium concentration£ between the two treatments, although albumin was
slightly lower in PD patients. The magnitude of the
difference in hematocrit and hemoglobin was simi-
I I
lar to that seen in diabetic patients, but greater scat-
6 12 18 24 30 36 42 48 ter in the data precluded significance. There was no
Time, weeks difference in bicarbonate concentrations in the two
groups of nondiabetic patients.
The results of the lipid studies (Table 5) show that
both PD and HD patients had lower levels of serum
cholesterol than did control subjects who were
somewhat younger. Triglyceride levels were, how-
Table 2. Hematologic and biochemical results
Table 2 shows hematologic and biochemical re-
sults. Significant differences emerged in both areas.
Hematocrit and hemoglobulin values were higher in
PD patients. The averages shown, however, do not
reflect that each group had a different pattern of re-
sponse. There was virtually no change in levels for
HD patients throughout the study. PD patients had
a brisk initial rise in hemoglobin and hematocrit,
followed by a plateau at the higher level for several
months, after which a gradual decline set in bringing
the 12-month figure very close to that prevailing in
HD patients (Fig. 1).
(A) r = 0.84
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Fig. 1. Hematocrit related to time on dialysis. In the first 24
weeks after entry into the study there was a rise in hematocrit in
patients on peritoneal dialysis (PD) (A) with r = 0.84 for that
period. In the next 24 weeks, there is a decline with r = 0.84
again for that time. Patients on hemodialysis (HD) (——) had no
significant change at all.
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Table 3. Morbidity and mortality of peritoneal and hemodialysis patients based on days at risk spent as hospital in-patients July 1, 1975 to
December31, 1978
Peritoneal Hemodialysis
Days at risk
Total hospital days
Initial dialysis admission
Shunt or fistula problems
Parathyroidectomy
Orthopedic problems related to renal osteodystrophy
or aseptic necrosis
Congestive heart failure or circulatory congestion
Hypertension
Peritoneal catheter problems
Peritonitis
Other complications related to dialysis
Other complications unrelated to dialysis but related to primary
systemic disease (i.e., diabetes mellitus, multiple myeloma, sys-
temic lupus erythematosis,
systemic vasculitis, amyloidosis, etc.)
Other complications unrelated to dialysis or underlying systemic disease
Number of patients in study
Number of patients expired
Number of patients removed from study (transplantation, change
of residence, refusal to participate, withdrew alive from
dialysis, lost partner)
5850 5850
696(11.9%) 474(8.1%)
7(0.1%) 0
175 (3.0%)
0 32(0.5%)
7(0.1%) 0
276(4.7%) 50(0.9%)
0 5 (0.09%)
80(1.4%) —
87(1.5%) —
5 (0.09%) 12(0.2%)
Table 4. Comparison of hematologic and biochemical resultsin diabetic and nondiabetic patientsa
Diabetic Nondiabetic
PD HD P PD HD P
BUN, mg/dl
Cr, mgldl
Nat, mEqiliterK, mEqiliter
Cl,mEqlliter
HC03, mEqiliter
Totalprotein,g/dl
Albumin, g/dl
Ca,mg/dl
Phosphate,mg/dl
Alk. Phos,kA units
Biirubin,mg/d/
SOOT, /ml
LDH,p.Iml
Uric acid, mg/dl
Hematocrit,%
Hemoglobin, gIdi
WBC, Xl03/mm
89.6
13.5
137.8
4.5
100.4
18.1
5.8
2.9
8.0
5.7
26.4
0.3
12.3
233.5
9.2
25.4
8.4
8.5
29.3
4.6
6.3
0.6
10.6
4.0
1.3
0.7
1.2
2.1
42.1
.2
19.6
78.1
2.4
3.8
1.1
2.6
95.7 30
15.1 5.4
137,9 6.0
5.5 1.0
100,2 8.5
13.2 2.7
7.4 1.0
4.1 0.5
8.8 0.9
5.7 2.0
26.5 13.4
0.5 10
16.2 25.6
208.7 82
9.1 1.9
23.8 4.2
7.4 1.3
8.5 2.1
NS
NS
NS
<0.001
NS
<0.001
<0.001
< 0.001
<0.001
NS
NS
NS
NS
NS
NS
< 0.05
<0.001
NS
85
13
140
4.8
102.7
18.9
6.5
3.5
9.0
5.5
28.1
0.43
19.5
197.3
8.7
28.1
8.7
8.3
23.2 (SD)
4.5
5.3
0.7
4.8
3.9
2.0
0.7
1.2
1.6
12.7
0.6
11.3
55
2.3
9.0
2.4
1.9
98.3 20.8
14.1 3.2
140.4 2.6
5.3 0.7
100.8 3.5
19.6 2.8
6.7 0.6
3.8 0.3
9.3 1.1
4.7 1.7
60.7 10.3
0.43 0.6
22.0 10.2
160.3 52
8.5 1.8
25.4 5.5
8.3 1.7
6.6 1.6
0.002
0.137
NS
0.001
NS
NS
NS
0.004
NS
0.017
0.02
NS
NS
0.004
NS
NS
NS
0.001
Values are the means SD.
ever, higher in both, especially in peritoneal pa-
tients. Within that group, females had the highest
values, but the numbers are too small to yield signif-
icance. High-density lipoprotein (HDL) levels were
lower than the control values were for HD patients
but not for PD patients. Both groups of dialysis pa-
tients had levels of alpha1 acid glycoprotein above
those of control (P < 0.001). Serum triglyceride val-
ues and levels of alpha1 acid glycoprotein showed a
direct correlation in both treatment groups (P <
0.001 for each) as shown in Fig. 2.
Neurophysiologic data showed that both treat-
ment groups had more slow-wave activity than a
control population. A significant correlation of
slow-wave activity (3-7/3-13 index using F3-01,
electrode linkage) with BUN was found (P < 0.002)
for the entire group. No such correlation was found
for creatinine. The correlation was quite strong (P
< 0.004) for patients treated by PD, but was not
significant (P = 0.28) for HD patients (Fig. 3). More
slow-wave activity appeared in the HD group. The
latency of the visual evoked responses was pro-
160(2.7%)
65(1.1%)
16
4
12
79 (1.4%)
112(1.9%)
16
2
14
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Table S. Average lipid measurements—control, peritoneal, hemodialysis populationsa
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Controls Peritoneal Hemodialysis
Age,yr 43 11 (20) 53 13 (7) 52 14 (7)
Cholesterol, mg/dl 206 35 (20) 183 38 (7) 160 36 (7)
Triglycerides, mg/dl 90 40 (20) 173 87" (7) 158 775 (7)
High-density lipo-
protein cholesterol, mgldl 50 8 (20) 40 8 (7) 33 10" (7)
Low-density lipo-
protein cholesterol, mgldl 128 13 (20) 108 27 (7) 93 25" (7)
Very-low-density lipo-
protein cholesterol, mg/dl 20 9 (20) 33 20" (7) 34 15" (7)
Free fatty acids, ,s.Eqlliter 684 257 (20) 510 223 (6) 492 120 (6)
Total lipoprotein lipase
activity,pinoles/mIFFA/hr 17.8 5.3(20) 6.1 2.9(6) 9.7 4.8(6)
Hepatic lipoprotein lipase
activity,p.moles/m1FFA/hr 13.1 5.4(20) 3.5 1.6(6) 7.0 4.4(6)
Adipose lipoprotein lipase
activity, p,noles/,nlFFAIhr 4.7 2.0 (20) 2.6 1.8 (6) 2.7 1.0 (6)
a Values are the means SD. Numbers of patients are given in parentheses.
1p < 0.05, comparison with controls.
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a1 -AGP, mg/d/
FIg. 2. Close correlation between serum triglyceride levels and
values of ai acid glycoprotein.
0.10
0.05
0
0 Peritoneal dialysis
r= 0.6490
P 0.004
longed in peritoneal patients compared with both
controls and HD patients. Higher BUN levels tend-
ed to be associated with higher amplitudes of peaks
IV and V, especially in HD patients (Fig. 4). There
was a positive correlation of creatinine with latency
(P = 0.045) and amplitude (P = 0.014) for peak V.
Photic-driving responses showed lower amplitude
at the fundamental and harmonic frequencies, but
higher at the subharmonic frequencies in the pa-
tients compared with control subjects. This was ac-
centuated in HD patients. Complete tabulation of
indices, linkages, correlations, and significance of
neurophysiologic data obtained has been described
elsewhere [18].
I I I I I I
10 20 3040 5060 70 8090100110 130 150 170
Blood urea r,itrogen,mg/dI
Fig. 3. Peritoneal dialysis patients showing a relationship be-
tween BUN values and slow-wave activity. This correlation did
not hold for hemodialysis patients, despite the fact that they had
more slow-wave activity.
Discussion
This study is an effort to compare, prospectively,
two populations of dialysis patients, one treated by
hemodialysis, the other by peritoneal dialysis.
When the study was designed, we decided to con-
trol entry to assure that in preordained ways the
two groups would be comparable. Because of the
relatively small pool (approximately 200 patients) to
draw from, we felt that random selection of treat-
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ment modality might result in unequal numbers of
nephrotics, or diabetics, or polycystic patients in
one or the other group, thus randomly but ef-
fectively skewing the results. We, therefore, chose
to control entry as described, accepting the disad-
vantages of a nonrandomized study.
Hematologic data indicate that patients treated
with PD have a significant rise in hemoglobin con-
centration shortly after beginning treatment. This
persisted for 6 to 9 months, then gradually fell to a
level comparable to the relatively unchanging value
of hemoglobin found in hemodialysis patients. The
cause of this phenomenon is not known. If the
cause were elimination of blood loss consequent to
HD, or to more effective removal of a toxic solute
poorly cleared by HD, the rise in hemoglobin
should persist. These two factors, therefore, may
initiate the rise that is seen in hemoglobin but not
the fall. Because PD removes protein species that
do not cross HD membranes, it is possible that pa-
tients become depleted of a solute related to
erythropoietin, or to red cell maturation, release, or
survival.
Certain of the biochemical differences are signif-
icant. The difference in BUN may relate to protein
and nonprotein nitrogen losses during dialysis, to
increased anabolism, or to decreased catabolism.
Our data do not permit distinction among these pos-
sibilities. Because this result was not anticipated,
five patients from each group were asked to compile
a 5-day diet diary while continuing on therapy. The
peritoneal patients averaged an intake of 1816 calo-
ries and 1.02 g of protein/kg/day, whereas HD pa-
tients consumed 1500 calories and 0.85 of proteinl
kglday. Body surface area was virtually identical
for the two groups. The difference of 0.01 ml/min
in residual urea clearance between groups does not
explain the difference noted. In short, our data in-
dicate that PD patients consume a less restrictive
diet and have a better BUN, bicarbonate, and po-
tassium concentration. The less normal albumin and
calcium concentrations documented resulted in no
symptoms or detectable adverse effect.
Our lipid and lipoprotein data confirm previous
findings of hypertriglyceridemia among PD and HD
patients [6, 19]. We did not, however, demonstrate
a significant difference between PD and HD as ob-
served by Cattran et al [61. The studies, however,
are not strictly comparable, and larger data gath-
ered prospectively will be needed with careful at-
tention to variables such as diet, drugs, and co-mor-
bid conditions. Similarly, we noted lower values for
HDL cholesterol in dialysis patients as noted else-
where [20]. HDL levels in HD patients were lower
than those observed in controls. This was not the
case for PD patients, whose values were lower, al-
though not significantly so, than controls. It is, of
course, possible that the small difference between
controls and PD patients might reach significance if
a larger sample size had been used. This issue is
important, for HDL levels have an inverse relation-
ship with risk of atherogenesis [21, 22] and the rela-
tive preservation of HDL values may represent an
advantage to PD patients. Because Felts, Staprans,
and Zacherle [23] reported that alpha1 acid glyco-
protein normalized the disappearance time of inject-
ed intralipid in rats with puromycin amino-
nucleoside nephrosis, and that orosomucoid was re-
coverable from peritoneal dialysis fluid, we
measured levels in controls and patients on HD and
PD. We found no evidence of deficiency in either
group.
Neurophysiologic studies demonstrate that the
two treatments affect the central nervous system
differently. Possible explanations include dif-
ferences in solute species retained or removed, the
rate of removal, nutrition, acid-base status, or other
factors. There is a positive correlation between
neurophysiologic abnormalities for some indices
and linkages and the BUN, or less often the creati-
nine. Results from this aspect of the study do not
permit us to discriminate between treatments for
specific patients, for example, epileptics. But the
data do show that HD patients had more changes in
background EEG and photic-driving responses,
whereas PD patients showed changes mainly in the
visual-evoked potential.
The opportunity to follow a total of 14 diabetic
patients matched for age, sex, duration of dialysis,
and other factors permitted collection of the data
given in Table 4. These results do not show a dra-
matic difference between the forms of treatment,
and do not support a contention that either HD or
PD is better for diabetic patients. Because formal
ophthalmologic evaluation of these patients was not
done, we cannot comment on progression of reti-
nopathy, but none of the patients in either group
became blind in a previously sighted eye during the
course of the study. The sad fact that all of the
deaths occurred in patients with diabetes simply
underscores the difficulty of treating such patients.
The emergence of continuous ambulatory perito-
neal dialysis (CAPD) as a treatment alternative [24,
25] has suggested to some that intermittent perito-
neal dialysis (IPD) may become obsolete. That may
not be the case, as the incidence of peritonitis is
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increased in CAPD patients and there are other
problems, including hypotension, back pain, and
hypertriglyceridemia [26]. Nonetheless, it might be
suspected that either form of peritoneal dialysis
would give results at least as good as these. CAPD
may or may not be better.
Our own summary of advantages and disadvan-
tages of intermittent HD and intermittent PD is
shown in Table 6. Review of these considerations
with the patient should permit selection of therapy
that will be personally most appropriate and satis-
fying. For example, HD is widely available so that
the patient who travels for business or pleasure can
make arrangements with only modest difficulty in
most cases. The duration of treatment is only one-
third that required for PD, and there are certain bio-
chemical advantages. The use of heparin poses,
however, unavoidable risks, and periodic trans-
fusions always carry a hazard of hepatitis to patient
and staff alike. The PD patient is faced with a far
greater time commitment and the probEems of peri-
tonitis or skin tunnel infection. These drawbacks
are balanced by the more liberal diet and more nor-
mal BUN, potassium, serum bicarbonate, and he-
matocrit. The higher hematocrit reduces the num-
ber of transfusions required. An individual who, be-
cause of concurrent colitis or angina, needs to avoid
heparin or maintain a higher hematocrit might be a
good candidate for PD. A patient whose defenses
against infection are compromised might better be
advised to try HD. Careful evaluation of what each
treatment has to offer to an individual patient
should permit thoughtful and appropriate selection
of therapy.
Table 6. Advantages and disadvantages
Hemodialysis Peritoneal dialysis
Advantages
Shorter treatments Liberal diet
Simplicity
Widely available Easier home dialysis
More normal: More normal:
Total protein BUN
Albumin Potassium
Serum calcium Bicarbonate
Probably lower Hematocrit
serum triglycerides Probably better
preserved HDL
Disadvantages
Heparin Peritonitis
Hemorrhage Protein washout
Air embolus Time commitment
Hepatitis
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